TY - JOUR
T1 - In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A
AU - Ishimoto, Hidekazu
AU - Shibata, Mari
AU - Myojin, Yuki
AU - Ito, Hideyuki
AU - Sugimoto, Yukio
AU - Tai, Akihiro
AU - Hatano, Tsutomu
N1 - Funding Information:
This study was supported in part by Grant-in-Aid for Scientific Research (No. 17604005) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Urolithin A is a major metabolite produced by rats and humans after consumption of pomegranate juice or pure ellagitannin geraniin. In this study, we investigated the anti-inflammatory effect of urolithin A on carrageenan-induced paw edema in mice. The volume of paw edema was reduced at 1 h after oral administration of urolithin A. In addition, plasma in treated mice exhibited significant oxygen radical antioxidant capacity (ORAC) scores with high plasma levels of the unconjugated form at 1 h after oral administration of urolithin A. These results indicate strong associations among plasma urolithin A levels, the plasma ORAC scores, and anti-inflammatory effects and may help explain a mechanism by which ellagitannins confer protection against inflammatory diseases.
AB - Urolithin A is a major metabolite produced by rats and humans after consumption of pomegranate juice or pure ellagitannin geraniin. In this study, we investigated the anti-inflammatory effect of urolithin A on carrageenan-induced paw edema in mice. The volume of paw edema was reduced at 1 h after oral administration of urolithin A. In addition, plasma in treated mice exhibited significant oxygen radical antioxidant capacity (ORAC) scores with high plasma levels of the unconjugated form at 1 h after oral administration of urolithin A. These results indicate strong associations among plasma urolithin A levels, the plasma ORAC scores, and anti-inflammatory effects and may help explain a mechanism by which ellagitannins confer protection against inflammatory diseases.
KW - Anti-inflammatory activity
KW - Antioxidant activity
KW - Ellagitannin
KW - Urolithin A
UR - http://www.scopus.com/inward/record.url?scp=80052596190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052596190&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2011.07.086
DO - 10.1016/j.bmcl.2011.07.086
M3 - Article
C2 - 21843938
AN - SCOPUS:80052596190
SN - 0960-894X
VL - 21
SP - 5901
EP - 5904
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 19
ER -